Highest-materiality recent filing
Pure Bioscience raises $1.0M in private placement at $0.0553/share; directors invest
Closed private placement of 18,131,096 shares at $0.0553/share for $1.0M gross.
PURE Bioscience Q2 revenue up 13% to $443K; net loss narrows; USDA cert for PURE Clean
Net product sales Q2 $443K (up 13% YoY); six-month sales $1.15M (up 22% YoY).
PURE Bioscience Q3 net product sales up 11% YoY; net loss narrows to $580K
Net product sales $489K in fiscal Q3 ended Apr 30, 2025, up from $440K YoY.
PURE Bioscience Q2 net sales up 20% YoY to $391K; net loss narrows to $798K
Net product sales $391K for fiscal Q2 ended Jan 31, 2025, vs $325K a year ago (+20%).
PURE Bioscience reports FY 2024 net loss of $3.4M; product sales up 4.5% to $1.955M
Net product sales $1.955M in FY 2024 vs $1.871M in FY 2023, up $84K (4.5%).
Pure Bioscience secures up to $3M in convertible notes; initial $500k from director Tom Y. Lee
Initial tranche of $500,000 convertible promissory note placed with director Tom Y. Lee (affiliates).
Pure Bioscience raises $500K via convertible notes from director; up to $3M total
Initial $500,000 private placement of convertible promissory notes to accredited investors, including board member Tom Y. Lee.
PURE Bioscience Q2 net product sales $325K, net loss $1.0M; shifting to distributor model
Net product sales $325K in Q2 FY2024, down 18% from $396K YoY; net loss $1.002M vs $1.060M.
On May 1, 2024, the Board of Directors (the “Board”) of Pure Bioscience, Inc. (the “Company”) authorized and appointed Darin Zehr, as a member of the Board.
Max materiality 0.70 · Median 0.55 · Most common event earnings